Fujifilm Announces The Introduction Of A 10 Week Cell Line Development Timeline With Its Apollo™ X Advanced Mammalian Expression System
March 10, 2018 – Pharmaceutical –
FUJIFILM Diosynth Biotechnologies (Fujifilm), a leading Contract
Development and Manufacturing Organization (CDMO) with experience in the
development and manufacture of recombinant biopharmaceuticals and gene
therapies, has announced the reduction of cell line development
timelines with its Apollo X™ Advanced Mammalian Expression System.
Development and Manufacturing Organization (CDMO) with experience in the
development and manufacture of recombinant biopharmaceuticals and gene
therapies, has announced the reduction of cell line development
timelines with its Apollo X™ Advanced Mammalian Expression System.
The
introduction of new single step cloning technology, in combination with
the new Apollo X host cell line has allowed development timelines to be
significantly reduced. The Apollo X Advanced Mammalian Expression
System allows for cell line development for monoclonal antibody
expression in 10 weeks (transfection to generation of research cell
banks) using Sphere Fluidics Cyto-Mine Technology followed by Cell
Metric (Solentim) plate-based imaging. This approach allows Fujifilm to
provide visual evidence of monoclonality from different instruments and
at different time points. The workflow provides a high probability of
monoclonality (>99%) and the cloning method is also supported by
experimental and statistical data for multiple cell lines and model
monoclonal antibodies.
introduction of new single step cloning technology, in combination with
the new Apollo X host cell line has allowed development timelines to be
significantly reduced. The Apollo X Advanced Mammalian Expression
System allows for cell line development for monoclonal antibody
expression in 10 weeks (transfection to generation of research cell
banks) using Sphere Fluidics Cyto-Mine Technology followed by Cell
Metric (Solentim) plate-based imaging. This approach allows Fujifilm to
provide visual evidence of monoclonality from different instruments and
at different time points. The workflow provides a high probability of
monoclonality (>99%) and the cloning method is also supported by
experimental and statistical data for multiple cell lines and model
monoclonal antibodies.
“The accelerated
timeline moves the bottleneck in cell line development from one that is
limited by the need for multiple screening and cloning steps to one that
is limited by cell doubling time,” said Fay Saunders, head of upstream
mammalian cell culture, process development, at FUJIFILM Diosynth
Biotechnologies, U.K. site.
timeline moves the bottleneck in cell line development from one that is
limited by the need for multiple screening and cloning steps to one that
is limited by cell doubling time,” said Fay Saunders, head of upstream
mammalian cell culture, process development, at FUJIFILM Diosynth
Biotechnologies, U.K. site.
The Apollo X
Advanced Mammalian Expression System is capable of delivering industry
leading titres in excess of 10g/L and is a “manufacturing ready” cell
line with a robust support package to aid IND filing.
Advanced Mammalian Expression System is capable of delivering industry
leading titres in excess of 10g/L and is a “manufacturing ready” cell
line with a robust support package to aid IND filing.
About Fujifilm
FUJIFILM
Diosynth Biotechnologies an industry-leading Biologics Contract
Development and Manufacturing Organization (CDMO) with locations in
Billingham and Redcar, UK, RTP, North Carolina and College Station,
Texas. FUJIFILM Diosynth has over twenty five years of experience in the
development and manufacturing of recombinant proteins, vaccines,
monoclonal antibodies, among other large molecules, viral products and
medical countermeasures expressed in a wide array of microbial,
mammalian, and host/virus systems. The company offers a comprehensive
list of services from cell line development using its proprietary
pAVEway™ microbial and Apollo™ cell line systems to process development,
analytical development, clinical and FDA-approved commercial
manufacturing. FUJIFILM Diosynth Biotechnologies is a partnership
between FUJIFILM Corporation and Mitsubishi Corporation. For more
information, go to: www.fujifilmdiosynth.com.
Diosynth Biotechnologies an industry-leading Biologics Contract
Development and Manufacturing Organization (CDMO) with locations in
Billingham and Redcar, UK, RTP, North Carolina and College Station,
Texas. FUJIFILM Diosynth has over twenty five years of experience in the
development and manufacturing of recombinant proteins, vaccines,
monoclonal antibodies, among other large molecules, viral products and
medical countermeasures expressed in a wide array of microbial,
mammalian, and host/virus systems. The company offers a comprehensive
list of services from cell line development using its proprietary
pAVEway™ microbial and Apollo™ cell line systems to process development,
analytical development, clinical and FDA-approved commercial
manufacturing. FUJIFILM Diosynth Biotechnologies is a partnership
between FUJIFILM Corporation and Mitsubishi Corporation. For more
information, go to: www.fujifilmdiosynth.com.
FUJIFILM
Holdings Corporation, Tokyo, Japan brings cutting-edge solutions to a
broad range of global industries by leveraging its depth of knowledge
and fundamental technologies developed in its relentless pursuit of
innovation. Its proprietary core technologies contribute to the various
fields including healthcare, graphic systems, highly functional
materials, optical devices, digital imaging and document products. These
products and services are based on its extensive portfolio of chemical,
mechanical, optical, electronic and imaging technologies. For the year
ended March 31, 2018, the company had global revenues of $23.0 billion,
at an exchange rate of 106 yen to the dollar. Fujifilm is committed to
environmental stewardship and good corporate citizenship. For more
information, please visit: www.fujifilmholdings.com.
Holdings Corporation, Tokyo, Japan brings cutting-edge solutions to a
broad range of global industries by leveraging its depth of knowledge
and fundamental technologies developed in its relentless pursuit of
innovation. Its proprietary core technologies contribute to the various
fields including healthcare, graphic systems, highly functional
materials, optical devices, digital imaging and document products. These
products and services are based on its extensive portfolio of chemical,
mechanical, optical, electronic and imaging technologies. For the year
ended March 31, 2018, the company had global revenues of $23.0 billion,
at an exchange rate of 106 yen to the dollar. Fujifilm is committed to
environmental stewardship and good corporate citizenship. For more
information, please visit: www.fujifilmholdings.com.
All product and company names herein may be trademarks of their registered owners.
SOURCE FUJIFILM Diosynth Biotechnologies
Related Links
The Jonas Webb Building, Babraham Research Campus, Babraham, Cambridge CB22 3AT, United Kingdom
